NAD+
50000 mcg · Mon/Wed/Fri
Robert
Founder, F*CK Getting Old — independent researcher, not a medical professional.
Last reviewed · 3 cited sources
Evidence
- Human Studies
- 12
- Animal Studies
- 100
- Clinical Status
- Off-label
- Confidence
- Low
- Long-Term Safety
- Limited — most human data is short-term, and mostly on oral precursors rather than direct injection
What this score is: a measure of how much research exists and how far along it is (animal-only vs. human trials, research-stage vs. FDA approved) — not how safe, effective, or worth trying a compound is. A low score usually means “early stage” or “understudied,” not “bad.” A high score doesn’t mean “better” for your goals than a lower-scored one.
This is not my personal rating of the compound, not a recommendation, and not medical advice. It’s a general research synthesis for informational purposes only, not a live literature count. See the linked research and talk to a licensed clinician before making decisions based on it.
Mechanism
NAD+ is a coenzyme central to cellular energy metabolism and DNA repair. Direct injection or IV infusion is studied for raising cellular NAD+ levels as they decline with age; most rigorous human trials actually study oral precursors (NR, NMN) rather than direct NAD+ injection.
Common Protocols
- 50,000–100,000 mcg (50–100 mg) 2–3x/week, subcutaneous or IV
- Injection can cause noticeable flushing/discomfort at higher doses
Side Effects
- Flushing, nausea, or cramping (especially IV/rapid administration)
- Injection site discomfort
Interactions
- Limited formal interaction data; used cautiously alongside other mitochondrial-support compounds
Practical Details
- Cost
- $$
- Typical Vial Size
- 500 mg
- Storage
- Refrigerate after reconstitution; protect from light
Key Studies & Reviews
- Gallagher C, Emmanuel OO (2026). NAD+ supplementation for anti-aging and wellness: a PRISMA-guided systematic review. Ageing Res Rev. PMID 41655607.
- Grant R et al. (2019). A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD. Front Aging Neurosci. PMID 31572171.
- Martens CR et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. PMID 29599478.
Search the Research
NAD+ FAQ
What is the typical NAD+ dosage?
Commonly reported protocols: 50,000–100,000 mcg (50–100 mg) 2–3x/week, subcutaneous or IV; Injection can cause noticeable flushing/discomfort at higher doses. Our reference entry uses 50000 mcg, Mon/Wed/Fri. These reflect protocols reported in research and user communities, not a medical recommendation — dosing should be decided with a clinician.
What are the side effects of NAD+?
Reported side effects include: Flushing, nausea, or cramping (especially IV/rapid administration); Injection site discomfort.
Is NAD+ FDA approved?
NAD+ is not FDA approved for the uses discussed here; it is used off-label or through compounding pharmacies, with less oversight of quality and dosing.
How much research is there on NAD+?
Our evidence profile counts roughly 12 human and 100 animal studies, with low overall confidence. Long-term safety: Limited — most human data is short-term, and mostly on oral precursors rather than direct injection.
Does NAD+ interact with other drugs or supplements?
Limited formal interaction data; used cautiously alongside other mitochondrial-support compounds.
How do I reconstitute NAD+?
A common setup is a 500 mg vial mixed with 3 mL of bacteriostatic water, which puts a 50000 mcg dose at about 30 units on a U-100 insulin syringe. Use the reconstitution calculator with your own vial and dose to get exact numbers. Storage: Refrigerate after reconstitution; protect from light.
Related compounds
Energizing/mitochondrial, do not mix with BPC-157 in same syringe